EMA Authorised: Epoetin Alfa Hexal (epoetin alfa) — Hexal AG

View source ↗

Summary

The EMA authorised Epoetin Alfa Hexal (epoetin alfa) from Hexal AG to treat anemia associated with chronic kidney disease and related conditions, including myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease
• Myelodysplastic Syndromes

Drugs mentioned

• Epoetin Alfa Hexal (epoetin alfa)

Snippet

Status: Authorised. Therapeutic area: Anemia;Kidney Failure, Chronic;Blood Transfusion, Autologous;Myelodysplastic Syndromes. MAH: Hexal AG. Decision date: 11/07/2025